Upadacitinib and dexamethasone for newly diagnosed ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a combination of upadacitinib (a pill that calms the immune system) and high-dose dexamethasone (a steroid) as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this mix can safely raise platelet counts better than steroids alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with ITP and have not had any treatment for it yet.
- Your platelet count is very low (less than 30,000) OR you have significant bleeding and a platelet count below 50,000.
- You do not have other serious medical conditions like HIV, hepatitis, cancer, or uncontrolled heart disease.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This trial studies a short, high-dose steroid plan (prednisone plus dexamethasone) to treat immune thrombocytopenia (ITP) in children and raise low platelet counts. It may help reduce bleeding risk while using an approach tested in children soon after diagnosis.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.